SABCS15: Promising phase 1 results lead to phase 2 for ONT-380 in HER2+ breast cancer
(University of Colorado Anschutz Medical Campus) Results of an ongoing phase 1b clinical trial presented today at the 2015 San Antonio Breast Cancer Symposium show promise of the experimental anti-cancer agent ONT-380 against metastatic HER2+ breast cancer, especially against brain metastases commonly associated with progression of the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 9, 2015 Category: Global & Universal Source Type: news

Biomarker Driven Strategy for ER+/HER2- Invasive Breast CancerBiomarker Driven Strategy for ER+/HER2- Invasive Breast Cancer
Find out more about what's behind the design of the ALTERNATE Trial. Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2015 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Neoadjuvant use of pertuzumab in HER2-positive breast cancer: Hint of lesser benefit
(Institute for Quality and Efficiency in Health Care) In contrast to the use in advanced unresectable breast cancer, no positive effects have been proven. However, more patients discontinue treatment, particularly due to cardiac disorders. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2015 Category: Global & Universal Source Type: news

Tykerb –Lapatinib - A Targeted Biologic...
Tykerb (lapatinib) is a targeted biologic therapy given as treatment for HER2 positive metastatic breast cancer. Tykerb can be taken with Xeloda, another oral chemotherapy drug, to extend survival and prevent the progression of advanced breast cancer. Read about how Tykerb works, possible side effects and drug interactions. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - November 29, 2015 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Dual HER2 Inhibition Flops as Adjuvant Breast Ca Tx (CME/CE)
(MedPage Today) -- Lapatinib-trastuzumab no better than trastuzumab alone (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 23, 2015 Category: Hematology Source Type: news

New Studies Investigating the Use of KEYTRUDA® (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at Upcoming Congresses
Dateline City: KENILWORTH, N.J. First-Time Presentation of KEYTRUDA Compared to Chemotherapy in Advanced Non-Small Cell Lung Cancer From KEYNOTE-010 Study New Findings of KEYTRUDA in Novel Combinations with Other Immunotherapies in Advanced Melanoma First-Time Findings in Multiple Myeloma and ER-Positive/HER2-Negative Breast Cancer as Well as New Findings in Classical Hodgkin Lymphoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that data investigating t...
Source: Merck.com - Corporate News - November 17, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news

Why FDA should oversee laboratory developed tests
By: Peter Lurie, M.D., M.P.H. Today FDA is issuing a report that illustrates the real and potential harms to patients and to public health from certain laboratory developed tests (LDTs) – tests that are designed, manufactured and used in a single laboratory. When FDA first began regulating medical devices under the Medical Device Amendments in the 1970s, we chose not to enforce applicable regulatory requirements for LDTs because they were relatively simple tests generally confined to local labs, and often used for rare conditions. But times have changed. LDTs have increased in complexity and availability and are now ...
Source: Mass Device - November 17, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Blog FDA Source Type: news

Medtech approvals: FDA releases September 2015 PMAs
The FDA today released its list of the pre-market approvals it granted for medical devices in September 2015: Summary of PMA Originals & Supplements Approved Originals: 4 Supplements: 53 Summary of PMA Originals Under Review Total Under Review: 55 Total Active: 31 Total On Hold: 24 Summary of PMA Supplements Under Review Total Under Review: 611 Total Active: 461 Total On Hold: 150 Summary of All PMA Submissions Originals: 3 Supplements: 84 Summary of PMA Supplement PMA Approval/Denial Decision Times Number of Approvals: 53 Number of Denials: 0 Average Days Fr Receipt to Decision (Total Time): 127.6 FDA Ti...
Source: Mass Device - November 16, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news

Rare Her2 mutations may not always spur breast cancers on their own
(Johns Hopkins Medicine) Results of a new laboratory study by Johns Hopkins Kimmel Cancer Center researchers suggests that some rare 'missense' mutations in the HER2 gene are apparently not -- on their own -- capable of causing breast cancer growth or spread. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 10, 2015 Category: Cancer & Oncology Source Type: news

PharmaMar's novel ADC demonstrates anticancer activity in HER2-expressing
(Pharmamar) PharmaMar announced that its novel Antibody-Drug Conjugate (ADC) demonstrates strong anticancer activity in vitro and in vivo against tumors expressing HER2 derived from breast, gastric and ovarian cancers. The novel ADC MI130004 consists of a new marine-derived tubulin inhibitor that is covalently bound to the HER2 antibody trastuzumab via a non-hydrolysable linker. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 6, 2015 Category: Global & Universal Source Type: news

Ovarian cancer drug 'can help with some types of prostate cancer'
Conclusion Prostate cancer is common in the UK, so news of new treatment options is always welcome. However, this study does not show for certain that olaparib works better than no treatment, even for men with the DNA repair mutations identified in the study as responding to treatment. The first problem is the lack of a comparison group. We can see what happened to the men who took the drug, but not what might have happened if they had not taken it, or if they'd taken another type of treatment not already tried. And most of the men treated did not get any benefit from the drug. Only 16 of the 49 men assessed showed any s...
Source: NHS News Feed - October 29, 2015 Category: Consumer Health News Tags: Cancer Medication Older people Source Type: news

MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA® (pembrolizumab) for Advanced Gastric Cancer
Dateline City: ROCKVILLE, Md. and KENILWORTH, N.J. Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer ROCKVILLE, Md.and KENILWORTH, N.J. Language: English read more (Source: Merck.com - Product News)
Source: Merck.com - Product News - October 22, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news

HER2-Positive Breast CA Patients Prosper on Solo Chemo (CME/CE)
(MedPage Today) -- Patients with elevated tumor-infiltrating lymphocytes do better without additional Herceptin (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 15, 2015 Category: Hematology Source Type: news

Medical News Today: Scientists find cause of reduced drug sensitivity in HER2-positive breast cancer
In the presence of the HER2 inhibitor lapatinib, the tumor suppressor molecule FOXO changes role and desensitizes HER2+ breast cancer cells to the drug, leading to relapse. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 13, 2015 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Perjeta® gets regulatory green light for use in early HER2-positive breast cancer prior to surgery
Perjeta (pertuzumab) regimen nearly doubled number of women whose tumours are eradicated versus standard treatment (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 29, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Personalised medicine Practical therapeutics Oncology Research breast cancer her2 HER2-positive breast cancer herceptin Latest News NEOSPHERE perjeta TRYPHAENA Source Type: news

Biomarker may predict which HER2-negative breast cancer patients will benefit from targeted therapy
Brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond -- and which should switch to another kind of treatment -- new research suggests. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 17, 2015 Category: Science Source Type: news

Biomarker may predict who'll benefit from targeted therapy for HER2-negative breast cancer
(Case Western Reserve University) A multi-center team led by Case Western Reserve has demonstrated that brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond -- and which should switch to another kind of treatment. Their findings appear in this month's International Journal of Cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 17, 2015 Category: Cancer & Oncology Source Type: news

[Editors' Choice] Cytokine loops promote breast cancer
Blocking autocrine cytokine loops may suppress the growth of HER2-positive breast cancer. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - August 26, 2015 Category: Science Authors: Nancy Gough (mailto:ngough at aaas.org) Source Type: news

Medtech approvals: FDA releases May 2015 PMAs
The FDA today released its list of the pre-market approvals it granted for medical devices in May 2015: Summary of PMA Originals & Supplements Approved Originals: 5 Supplements: 51 Summary of PMA Originals Under Review Total Under Review: 55 Total Active: 26 Total On Hold: 29 Summary of PMA Supplements Under Review Total Under Review: 547 Total Active: 379 Total On Hold: 168 Summary of All PMA Submissions Originals: 1 Supplements: 62 Summary of PMA Supplement PMA Approval/Denial Decision Times Number of Approvals: 51 Number of Denials: 0 Average Days Fr Receipt to Decision (Total Time): 109.5 FDA Time: 86...
Source: Mass Device - August 6, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news

Roche's Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer
Roche today announced that the European Commission (EC) has approved the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - July 31, 2015 Category: Pharmaceuticals Source Type: news

Roche's Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer
Roche today announced that the European Commission (EC) has approved the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - July 31, 2015 Category: Pharmaceuticals Source Type: news

Guideline: Limit Biomarker Testing in Metastatic Breast Ca (CME/CE)
(MedPage Today) -- Current evidence supports HER2, hormone receptors tests, ASCO says. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - July 23, 2015 Category: Geriatrics Source Type: news

Researchers discover a possible reason for drug resistance in breast tumors
(INM -Leibniz Insitute for New Materials) Amplified levels of HER2 membrane proteins drive unrestricted cell growth in certain types of breast cancer. HER2-tailored antibody-based therapeutics aim to prevent cancer cell growth. However, two-thirds of the patients develop resistance against such therapeutics. Why, is not yet understood. Researchers now found out that HER2 dimers appeared to be absent from a small sub-population of resting SKBR3 breast cancer cells. This subpopulation may have self-renewing properties and thus may be resistant to antibody therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 17, 2015 Category: Cancer & Oncology Source Type: news

Drug Combo Effective for Metastatic HER2+ Breast Ca (CME/CE)
(MedPage Today) -- Metabolic imaging may identify poor responders in advance. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 15, 2015 Category: Hematology Source Type: news

NCI awards UC researcher $1.8 million to study protein's effect on breast cancer
(University of Cincinnati Academic Health Center) Xiaoting Zhang, Ph.D., associate professor in the Department of Cancer Biology at the University of Cincinnati College of Medicine, has received a $1.8 million, five-year, R01 award from the National Cancer Institute to continue breast cancer research focusing on the function of the protein MED1 on HER2-positive breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2015 Category: Cancer & Oncology Source Type: news

Inaccurate HER2 testing results in high economic societal loss
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2015 Category: Drugs & Pharmacology Source Type: news

EU CHMP recommends Roche’s Perjeta for pre-surgery use in breast cancer
The European Union (EU) Committee for Medicinal Products for Human Use (CHMP) has recommended for approval Roche's Perjeta along with Herceptin and chemotherapy for neoadjuvant treatment of adult patients with HER2-positive early breast cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 29, 2015 Category: Pharmaceuticals Source Type: news

Gene Gun Her2/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2/neu Mouse Tumor Model
Genetic vaccination using naked plasmid DNA is an immunization strategy both against infectious diseases and cancer. In order to improve the efficacy of DNA vaccines, particularly in large animals and humans, different strategies have been pursued. These vaccination strategies are based on different application routes, schedules, and coexpression of immunomodulatory molecules as adjuvants. Our mouse tumor model offers the possibility to investigate Her2/neu DNA vaccines in different settings, i.e., intramuscular or intradermal application with or without coexpression of adjuvants. Protection from tumor growth in tumor chal...
Source: Springer protocols feed by Cancer Research - June 27, 2015 Category: Cancer & Oncology Source Type: news

Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy
Aptamers are an emerging class of molecules in cancer therapy. They can be easily synthesized and are considered cost-effective drug candidates. In this book chapter we describe the selection and characterization of DNA aptamers specific to the human epidermal growth factor receptor 2 (ERBB2/HER2), an oncogenic tyrosine kinase. First, a DNA aptamer library is applied and ERBB2-specific aptamers are selected using SELEX. Binders are subcloned into a pGEM-T vector, sequenced, and characterized using biochemical and cell biological techniques. By multimerizing the selected ERBB2 aptamers, it might be possible to significantly...
Source: Springer protocols feed by Cancer Research - June 27, 2015 Category: Cancer & Oncology Source Type: news

EU Recommends Approval of Neoadjuvant Pertuzumab RegimenEU Recommends Approval of Neoadjuvant Pertuzumab Regimen
CHMP has cleared the way for approval of pertuzumab combined with traztuzumab and other agents in the neoadjuvant setting for women with early HER2-positive breast cancer. International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 27, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche’s Perjeta recommended for approval in EU for use before surgery in HER2-positive early breast cancer
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approves the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - June 26, 2015 Category: Pharmaceuticals Source Type: news

Roche’s Perjeta recommended for approval in EU for use before surgery in HER2-positive early breast cancer
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approves the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - June 26, 2015 Category: Pharmaceuticals Source Type: news

Neratinib Lowers Recurrence in High-Risk HER2+ Breast CancerNeratinib Lowers Recurrence in High-Risk HER2+ Breast Cancer
Dr Lidia Schapira gives the take-home messages from breast cancer sessions of ASCO 2015, including top studies in HER2+ and HR+ disease, and new findings for managing side effects of treatment. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

UCLA receives $1 million from Revlon to fund breast cancer research
UCLA has received a $1 million donation from Revlon that will support the Revlon/UCLA Women’s Cancer Research Program and further the company’s long-standing commitment to eradicating women’s cancers. The gift was announced by Revlon CEO Lorenzo Delpani, chairman Ronald O. Perelman and global brand ambassador Halle Berry at an event honoring Dr. Dennis Slamon, a member of the UCLA Jonsson Comprehensive Cancer Center and director of the Revlon/UCLA Breast Cancer Center Director for his outstanding achievements in cancer research. “We have made tremendous advancements in the field of breast cancer tre...
Source: UCLA Newsroom: Health Sciences - June 8, 2015 Category: Universities & Medical Training Source Type: news

HER2 Bladder Cancer: Mayo Clinic Radio Health Minute
In this Mayo Clinic Radio Health Minute, we hear from Dr. John Cheville about a study which looked as some similarities between some breast and bladder cancers. To listen, click the link below. HER2 Bladder Cancer (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 8, 2015 Category: Databases & Libraries Source Type: news

Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy
Roche today announced new results from the Phase II NeoSphere study. The results suggest that Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy given prior to surgery reduced the risk of disease getting worse and increased the time people lived without their cancer returning compared to Herceptin and chemotherapy in people with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - June 1, 2015 Category: Pharmaceuticals Source Type: news

Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy
Roche today announced new results from the Phase II NeoSphere study. The results suggest that Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy given prior to surgery reduced the risk of disease getting worse and increased the time people lived without their cancer returning compared to Herceptin and chemotherapy in people with HER2-positive early breast cancer (eBC). (Source: Roche Investor Update)
Source: Roche Investor Update - June 1, 2015 Category: Pharmaceuticals Source Type: news

Oncothyreon Announces Presentation of Positive ONT-380 Data in HER2-Positive Breast Cancer at ASCO Annual Meeting and Updates Development Plan
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - May 30, 2015 Category: Pharmaceuticals Source Type: news

ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About...
At ASCO 2015, University of Colorado Cancer Center reports promising clinical trial results of ONT-380 against HER2+ breast cancer(PRWeb May 30, 2015)Read the full story at http://www.prweb.com/releases/2015/05/prweb12756741.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 30, 2015 Category: Pharmaceuticals Source Type: news

ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'
Promising clinical trial results show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 29, 2015 Category: Science Source Type: news

ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'
(University of Colorado Denver) Promising clinical trial results presented at the American Society for Clinical Oncology Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 29, 2015 Category: Biology Source Type: news

[Research Article] HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive
Exploiting the dependence of some cancer cells on an ER stress response pathway may overcome resistance to some chemotherapeutics. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - May 26, 2015 Category: Science Authors: Navneet Singh, Rashika Joshi, Kakajan Komurov Source Type: news

SHAVE a Big Plus in Breast CancerSHAVE a Big Plus in Breast Cancer
Dr Kathy Miller makes her top picks of breast cancer studies to watch at ASCO, noting trials in ER-positive and HER2-positive disease--and a small surgical study that may yield big benefits. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 22, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

[Focus] A new strategy to ERADicate HER2-positive breast tumors?
Targeting a proteotoxic stress response pathway may improve therapeutic outcomes for HER2-positive breast cancer patients. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - May 22, 2015 Category: Science Authors: Sanjeevani Arora and Erica A. Golemis Source Type: news

Risk of Subsequent Breast Cancer in Human EGFR 2-Positive DCISRisk of Subsequent Breast Cancer in Human EGFR 2-Positive DCIS
What's the prognostic role of HER2 overexpression in patients with ductal carcinoma in situ? Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 11, 2015 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Is Genetic Testing for Breast Cancer Right for You?
Susan K. Boolbol, MD Chief, Division of Breast Surgery Mount Sinai Beth Israel For most women, the average risk of developing breast cancer is about 12 percent. However, if you have a mutation on either of the two most common genes associated with breast cancer -- BRCA1 and BRCA2 -- that risk can jump as high as 80 percent. While it's natural to wonder if you might have inherited an abnormal BRCA gene from one of your parents, it's also important to remember that only about 5-10 percent of breast cancers are due to hereditary mutations; the overwhelming majority of women with breast cancer have no family history of the di...
Source: Healthy Living - The Huffington Post - May 6, 2015 Category: Consumer Health News Source Type: news

Breast cancer vaccines may work better with silicon microparticles
The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists. Model studies showed that microparticles loaded with an antigen, HER2, not only protected the antigen from premature destruction, but also stimulated the immune system to recognize and relentlessly attack cancer cells overexpressing the HER2 antigen. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 5, 2015 Category: Science Source Type: news

HR+/HER2- Advanced Breast Cancer Pretreated With Non-Steroid AIsHR+/HER2- Advanced Breast Cancer Pretreated With Non-Steroid AIs
Compare results of trials on endocrine or targeted treatment in HR+/HER2- mBC patients who progressed after a prior NSAI therapy. Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2015 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

HER2 Dependency in Lung CancersHER2 Dependency in Lung Cancers
What have we learned about treating HER2-mutant lung cancers? Dr Mark Kris explores this new topic in the field of thoracic oncology. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 29, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Master switch for cancer-causing HER2 protein identified
Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 28, 2015 Category: Science Source Type: news